News

Essentra has signed an agreement to acquire Clondalkin's Specialist Packaging Division for a cash consideration of approximately $455 million.

Consort announced that it has completed the acquisition of Aesica.

As the second part of this series, we look at the importance of ?assessing? the punches and dies to check their condition and how this step may help avoid any problems that may occur during tablet manufacture.

ANSM wants company data on the benefits and risks of using Avastin over Lucentis in the treatment of wet age-related macular degeneration.

Facility will provide manufacturing services for inhalation, liquids, topicals and oral solids dosage forms

Catalent Pharma Solutions announces additional packaging and storage space for highly potent and cytotocix drugs at Kansas City facility.

Capsugel gives lead users access to intrinsically enteric capsule technology and support services.

SGS Life Science Services has been awarded cGMP accreditation from AIFA for its analytical laboratory in Livorno, Italy.

The deal between the two companies will strengthen Perrigo's presence in Europe.

Roche announced it will spend 450 million Swiss Francs on a new manufacturing facility in Suzhou, China.

FDA releases guidance specifying its preferred unique facility identifier system.

FDA gives orphan drug designation to Merrimack Pharmaceuticals MM-141 for the treatment of pancreatic cancer.

M&A transactions accounted for nearly $15 billion more this year than for the same period a year ago.

Construction has started on Novo Nordisk's laboratories for diabetes research in Denmark.

MedImmune enters into an agreement to acquire the image analysis and data mining company.

AstraZeneca announced a partnership with Pharmacyclics and Janssen for combination trials of MEDI4736 (AstraZeneca) with Imbruvica (Pharmacyclics and Janssen) for the treatment of hematologic cancers.

An FDA warning letter to Hikma Pharmaceuticals cites violations of CGMP at its plant in Portugal that manufactures finished drugs.

Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.

LabCorp announced it will purchase contract research company Covance Inc. for approximately $6.1 billion in cash and stock.

Spectranetics announced that it acquired Covidien's drug-coated balloon platform, Stellarex, for $30 million.

Ebola Virus Disease (EVD) is a severe, often fatal disease that is transmitted human-to-human through bodily fluids.

Industry veteran Peter Bigelow to guide PBOA Board.

Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.

The final guidance explains some principles for developing biosimilars and establishes some rules about extrapolation across indications for various medical conditions.

Sigma-Aldrich's custom manufacturing services business unit, SAFC, has launched a new protein quality supplement for biological drug production, including biosimilars.

Gerresheimer, a company with expertise in pharmaceutical and medical technology, announced that it is applying an integrated mold qualification and validation concept for a fast and cost-efficient time-to-market. The company notes that this approach provides process windows for reliable large-scale production and offers options for different deployment scenarios and qualification levels.

SGS Life Science Services announced the completion of its Glasgow, UK testing facility for cell banks in biological medicines.

CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.

The new Argos biomanufacturing facility in North Carolina will include automated production using the company's Arcelis technology.

Bristol-Myers Squibb announced that they have reached an agreement with F-star Alpha, giving BMS the exclusive option to acquire F-star's HER2-targeted breast and gastric cancer treatment.